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ABSTRACT
Allergic diseases are complex diseases caused by a combination of genetic and environmental factors. To de-
termine the genetic components of these diseases and to discover the genes and cellular pathways underlying
them, a large number of genetic studies have been conducted. Progress in genetics enables us to conduct
genome-wide association studies (GWASs), which is a comprehensive and unbiased approach to identify sus-
ceptibility loci for multifactorial diseases. Recent GWASs have convincingly detected a large number of loci as-
sociated with allergic diseases. Candidate genes in the susceptibility loci suggest roles for epithelial barrier
functions, innate-adaptive immunity, IL-1 family signaling, regulatory T cells and the vitamin D pathway in the
pathogenesis of allergic diseases. Interestingly, the IL1RL1, HLA, IL13 and C11orf30 regions are overlapping
susceptibility loci among atopic dermatitis and asthma or allergic rhinitis. Although a more complete collection
of associated genes and pathways is needed, biologic insights revealed by GWASs improve our understanding
of the pathophysiology of human allergic diseases and contribute to the development of better treatment and
preventive strategies.
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INTRODUCTION
The genome is the set of all genes, regulatory se-
quences and other information included in the non-
coding regions.1,2 The Human Genome Project is a
coordinated international project with the primary
goal of determining the consensus sequence of the
human genome.1,2 After the draft sequence of the hu-
man genome was reported in 2001, researchers fo-
cused on the genomic variation among individuals.3-6
A base variation is referred to as a single-nucleotide
polymorphism (SNP), and humans have a heterozy-
gous site roughly every 300 bases in their genome.5
It has been suggested that there are about 10 million
SNPs across the genome and one million SNPs in
gene regions.5 Some of them, especially around
genes, are considered to influence variations in the
timing, amount, or function of a protein produced
from a gene and to contribute to disease risk. Most
common diseases are caused by the interaction of ge-
netic and environmental factors, and genetic vari-
ations are a component of the genetic factors. To dis-
cover disease-related gene variations, a large number
of case-control studies, which compare the frequen-
cies of alleles or genotypes between cases and con-
trols, have been conducted.7 Since the 1990s, associa-
tion studies for allergic diseases using the candidate
gene approach have been performed in various eth-
nic populations.8 The candidate gene approach is
hypothesis-driven and the findings are easy to inter-
pret; however, these studies cannot identify novel
susceptible genes or pathways. Furthermore, some of
the studies had issues such as the lack of statistical
power and replication study, insufficient polymor-
phism coverage of a gene, and small sample sizes.9
The ‘common disease-common variant’ hypothesis
predicted that common genetic variants could play a
role in the etiologies of common diseases.10 The
genome-wide association study (GWAS) is a test of
the association between common genetic variants
spreading across the genome and disease.11,12 Com-
prehensive, well-powered, genome-wide surveys us-
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ing GWAS have revealed disease susceptibility
loci.11,12 GWASs have accelerated biomedical re-
search to discover the genes and cellular pathways
underlying disease in an unbiased and hypothesis-
free manner.7 This review focuses on GWAS of aller-
gic diseases, and we also discuss the road ahead for
the genetics of allergic diseases.
GENOME-WIDE ASSOCIATION STUDIES
The international HapMap project (http:hapmap.nc
bi.nlm.nih.gov) started in 2002 to develop a public
database that could help researchers find genes asso-
ciated with human diseases and individual responses
to pharmacological agents.5,6 The HapMap project fo-
cuses only on common SNPs with minor allele fre-
quencies >1% in the population and defines these pat-
terns across the whole genome. The discovery of the
haplotype structure of the human genome indicated
that a limited set of 1,000,000 SNPs could capture
-90% of the genetic variation in the population.7 The
data from the HapMap project and the development
of dense genotyping arrays have enabled us to per-
form GWASs on a large number of samples. Genotyp-
ing arrays have been developed with reference to
linkage disequilibrium, and are now able to assay up
to -2 million variants. However, if large numbers of
SNPs are assessed simultaneously in a GWAS, the
statistical significance threshold must be adjusted for
type 1 errors (false positive). Generally, a genome-
wide significance threshold level of 5 × 10－8 (0.05
1,000,000) is applied if a test of independence is per-
formed for 1,000,000 SNPs with a conventional P
value < 0.05 for significance.11
Genotype imputation is a statistical approach de-
ducing the allelic states at polymorphic sites not actu-
ally genotyped from the surrounding SNP data, based
on linkage disequilibrium and likelihood estimates.13
Recently, a number of GWAS consortiums have been
founded with the aim of conducting rigorous statisti-
cal and comprehensive GWAS meta-analyses for com-
mon disorders. Imputation is useful for merging dis-
tinct GWASs using different genotyping platforms
and enables powerful combined analyses of GWASs
for the discovery of novel associations.13,14 A collabo-
rative Transnational Asthma Genetics Consortium
(TAGC) bringing GWASs from all over the world to-
gether and completing a meta-analysis for asthma ex-
amining over 30,000 cases and 50,000 controls is now
ongoing.
GWASs OF ASTHMA
Bronchial asthma is a heterogeneous disease caused
by a combination of genetic and environmental fac-
tors.8 A large number of genetic studies using the
candidate gene approach have been conducted to dis-
cover the genes and cellular pathways underlying
asthma.8,9,15 Recently, systemic, well-powered, genome-
wide surveys using GWASs have explored the rela-
tionship between SNPs and asthma susceptibility.
The findings of GWASs of asthma imply the impor-
tance of genes that play a role in communication of
epithelial damage to the adaptive immune system and
activation of airway inflammation.8,9,15
The first GWAS of asthma identified a locus on
chromosome 17q21.1 that contributed to the risk of
childhood asthma.16 Genetic variants in the locus
were strongly correlated in cis with transcript levels
of ORMDL3 in Epstein-Barr virus (EBV)-transformed
lymphoblastoid cell lines from children with asthma.
A number of studies in various ethnic populations
replicated the association; however, it appears that
the region is associated with childhood, but not adult-
onset, asthma.17-22
Sleiman et al. conducted a GWAS involving chil-
dren with persistent asthma who required daily in-
haled glucocorticoid therapy and matched controls,
and identified a novel asthma-susceptible locus on
chromosome 1q31, which contains CRB1 and
DENND1B. The latter is expressed in dendritic cells
and activates T cells.23
A recent large-scale, consortium-based GWAS of
asthma was performed with 10,365 cases and 16,110
controls and identified six susceptible loci containing
IL1RL1IL18R1, HLA-DQ, IL33, SMAD3, ORMDL3
GSDMB and IL2RB.24 The ligand for IL1RL1 is IL-33,
which has been shown to be important in Th2-
associated disease models.25 IL-33 is considered to be
important for host defense against nematodes by in-
ducing T helper type 2 (Th2) cytokine production via
IL-33 receptors and is also a key cytokine for induc-
ing and activating innate lymphoid cells.26 These find-
ings imply that genetic factors involved in the IL-33
pathway play an important role in the pathophysiol-
ogy of human bronchial asthma.
In 2011, a meta-analysis of GWASs of asthma in
ethnically diverse North American populations was
reported.27 The study examined reports on individu-
als of European American, African American or Afri-
can Caribbean, and Latino ancestry and identified a
total of five susceptibility loci. Four loci on 17q21,
near IL1RL1, TSLP and IL33 were already reported
regions.24,28 A new asthma susceptibility locus at
PYHIN1 was identified with the association being
specific to individuals of African descent.
In 2011, we conducted a GWAS of adult asthma in
the Japanese population and reported five candidate
loci.29 The most significant association with adult
asthma was observed at rs404860 in the major histo-
compatibility complex (MHC) region on chromo-
some 6p21, which is close to rs2070600 previously re-
ported for association with FEV1FVC by GWASs for
lung function.30,31 Reduction of FEV1FVC is a char-
acteristic of obstructive lung diseases such as
asthma. There might be an important common ge-
netic determinant of lung function in both healthy in-
dividuals and asthma at the locus. An associated re-
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Table　1　Susceptibility loci of atopic dermatitis identifi ed by 
GWAS
Popula-
tions Ref.
Chro-
mosome Genes
European ref. 46 11q13.5 C11ORF30/LRRC32 
(GARP)
Chinese ref. 47 1p21.3 FLG
5q11.1 TMEM232/SLC25A46
20q13.3 TNFRSF6B/ZGPAT
European 
Meta
ref. 48 11q13 OVOL1
19p13.2 ACTL9
5q31 KIF3A/IL4/IL13
Japanese ref. 53 2q12 IL1RL1/IL18R1/IL18RAP
3p21.33 GLB1
3q13.2 CCDC80
6p21.3 the MHC region
7p22 CARD11
10q21.2 ZNF365/EGR2
11p15.4 OR10A3/NLRP10
20q13 CYP24A1/PFDN4
gion on chromosome 5q22 includes the TSLP gene.
TSLP derived from epithelial cells induces Th2 cell-
type inflammation and is involved in the pathogenesis
of asthma.32 Interestingly, the TSLPWDR36 locus is
associated with bronchial asthma across ethnic lines
with genome-wide significance.27 A recent study has
shown that treatment with corticosteroids and sal-
meterol synergistically suppresses poly(I:C)-induced
TSLP in airway epithelial cells.33 Thus, TSLP might
be a therapeutic target molecule for combination
therapy (corticosteroidslong-acting beta-agonists)
during respiratory viral infections.33 The locus on
chromosome 4q31 contains USP38-GAB1. USP38 en-
codes ubiquitin-specific peptidase 38, whose function
is unclear. GAB1 is a scaffolding adopter protein that
plays an important role in the signaling pathway acti-
vated by cytokine receptors for IL-3, IL-6, interferon α
and γ, and B-cell and T-cell receptors.34 The locus on
chromosome 10p14 is a gene desert and is located 1
Mb downstream from GATA3, a master regulator of
Th2 differentiation.35 The susceptible locus on chro-
mosome 12q13 is a gene-rich region and contains
IKZF4 (also known as EOS). The peak association is
observed 2 kb upstream from IKZF4, which was
shown to be involved in differentiation of regulatory T
cells as a coregulator of FOXP3-directed gene silenc-
ing.36 Regulatory T cells maintain pulmonary homeo-
stasis and prevent harmful immune responses to in-
nocuous inhaled antigens.37
A GWAS of asthma using an Australian population
has been conducted and identified associations of
rs4129267 in the interleukin-6 receptor (IL6R) gene
and rs7130588 on chromosome 11q13.5 near the
leucine-rich repeat containing 32 gene (LRRC32, also
known as GARP) with genome-wide significance.38
The study suggested the possibility that an IL6R an-
tagonist might be effective to treat the disease, per-
haps in a genotype-dependent manner.38
Severe asthma is an important phenotype in
asthma research. Approximately 5% of patients have
severe asthma that is difficult to control with maximal
inhaler therapy.39 Li et al. focused on patients with se-
vere or difficult-to-treat asthma and performed a
GWAS.40 A total of 292,443 SNPs were surveyed with
imputation analysis in cases from The Epidemiology
and Natural History of Asthma: Outcomes and Treat-
ment Regimens (TENOR) population and Illumina
general population control subjects. Imputation was
also performed in identified candidate loci. Their
study finally identified two loci associated with
asthma, the RAD50-IL13 region on chromosome
5q31.1 and HLA-DRDQ region on chromosome
6p21.3.40 These findings imply the important role of
Th2 cytokine and antigen presentation genes in se-
vere or difficult-to-treat asthma.
Pharmacogenetic studies in asthma using GWASs
have been reported. A recent study identified genetic
variants associated with lung function changes (post-
FEV1-pre-FEV1)pre-FEV1) in response to inhaled
corticosteroids.41 A functional GLCCI1 variant is asso-
ciated with substantial decrements in the inhaled cor-
ticosteroid response in asthma.41 The low responder
allele shows significantly lower enhancer activity than
the other allele.41 Interestingly, GLCCI1 is induced
by corticosteroids in human B cells in response to
costimulation with IL-4 and anti-IgM.41 The findings
suggest that GLCCI1 is a target molecule of glucocor-
ticoid in B cells under the Th2 condition.
GWASs OF ATOPIC DERMATITIS
Atopic dermatitis is a chronic skin disease involving
skin barrier dysfunctions and cutaneous inflamma-
tory hypersensitivity with a strong genetic basis. Pa-
tients with atopic dermatitis are particularly suscepti-
ble to a number of microbial organisms, and pruritus
is a major symptom of atopic dermatitis.42,43 The itch-
scratch cycle can lead to damage to the epidermal
keratinocytes.42 Table 1 summarizes the findings
from recent GWASs of atopic dermatitis, and genes
within identified atopic dermatitis susceptibility loci
are shown. A recent study has reported that common
loss-of-function variants in FLG (encoding filaggrin)
are a major predisposing factor for atopic dermati-
tis.44 A number of association studies in populations
of diverse ancestry, meta-analyses of such studies
and GWASs have reported that mutations in FLG are
strongly associated with atopic dermatitis.45 Apart
from FLG, recent GWASs of European and Chinese
populations and a meta-analysis of GWASs have iden-
tified six susceptibility loci of atopic dermatitis with
genome-wide significance.46-48
The first GWAS of atopic dermatitis identified a
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susceptible locus on chromosome 11q13.5, located 38
kb downstream of C11orf30.46 The locus contained
LRRC32. LRRC32 mRNA is highly expressed in acti-
vated FOXP3+ regulatory T cells, and LRRC32 is es-
sential for the surface expression of latent TGF-β on
the cells.49 In the GWAS, an additional association
signal was observed in the epidermal differentiation
complex on chromosome 1q21. The region is located
adjacent to FLG and contains a number of genes that
play roles in epidermal structure and function.50
A GWAS for atopic dermatitis in the Chinese Han
population identified two new susceptibility loci at
5q22.1 and 20q13.33 and confirmed an association be-
tween the FLG locus and atopic dermatitis at the
genome-wide level of significance.47 The 5q22.1 locus
contains TMEM232 and SLC25A46, but little is
known about the functions of the genes.47 Interest-
ingly, the region is located adjacent to the TSLP
gene; however, the influence of the associated vari-
ants in the region on the expression of the TSLP
gene remains unclear. The 20q13.33 region contains
eight genes, including the TNFRSF6B gene, which
encodes decoy receptor 3 (DcR3).47 DcR3 is a se-
creted protein belonging to the tumor necrosis factor
receptor family (TNFRSF) and it binds to LIGHT. A
recent study has shown that LIGHT is a target for
asthmatic airway remodeling.51
In 2011, a meta-analysis of GWAS reported three
novel susceptibility loci for atopic dermatitis.48 The
peak associations were observed at rs479844 up-
stream of OVOL1 and rs2164983 near ACTL9, both of
which are near genes that have been implicated in
epidermal proliferation and differentiation, as well as
rs2897442 in KIF3A at 5q31.1.48 The locus at 5q31
contains a cluster of cytokine and immune-related
genes and has been associated with several autoim-
mune and inflammatory diseases including asthma
and psoriasis.24,52 Interestingly, conditional logistic
regression analysis indicated that the association sig-
nal within the cytokine cluster at 5q31.1 appeared to
be composed of two independent signals, one cen-
tered at IL13-RAD50 and the other at IL4-KIF3A.48
These findings suggest that the genetic region con-
taining IL4 and IL13 influences the development of
both atopic dermatitis and asthma.
In 2012, we reported a GWAS and a validation
study comprising a total of 3,328 cases and 14,992
controls in the Japanese population.53 Analyzing a to-
tal of roughly 600,000 genetic variants, a total of eight
new genetic regions associated with atopic dermatitis
were identified.53 The study confirmed the seven loci
observed in earlier studies.53 The associated region at
2q12 contains the receptors of IL-1 family cytokines
IL1RL1, IL18R1 and IL18RAP. IL-1 family members
are abundantly expressed in the skin, and IL1RL1 is a
component of the IL-33 receptor, which is expressed
by Th2 cells and mast cells.25,54 Interestingly, IL-33 is
secreted in damaged tissues of atopic dermatitis and
promotes Th2-type immune responses and the patho-
genesis of atopic dermatitis.25 The most significant
association at the locus is found in the MHC class III
region. In the GWAS, after conditional analysis, there
were two independent association signals in the
MHC class I and class III regions. The involvement of
autoimmunity has been suggested in chronic inflam-
mation in patients with atopic dermatitis.42 IgE anti-
bodies against keratinocytes and endothelial cells are
observed in serum specimens from subjects with se-
vere atopic dermatitis.55 Since the MHC is associated
with a number of autoimmune diseases,56 further ex-
periments will be required to clarify where the sus-
ceptibility genes are located precisely. The region of
association at 11p15.4 contains NLRP10, which be-
longs to the NALP protein family but lacks the
leucine-rich repeat region. A recent report has shown
that NLRP10 is essential to initiate adaptive immunity
by dendritic cells.57 Another study has shown that
NLRP10 plays a role in the control of disseminated C.
albicans infection in vivo through the generation of
adaptive immune responses such as Th1 and Th17 re-
sponses, to fungal infection.58 The chromosome
3p21.33 region is located adjacent to the CCR4 gene,
which encodes a Th2-associated chemokine receptor
for CCL22 and CCL17 (TARC). CCR4 mediates skin-
specific recruitment of T cells during inflamma-
tion.42,59 Keratinocyte-derived TSLP induces dendritic
cells to produce TARC, and serum TARC levels are
useful for evaluation of the disease activity of AD.42,59
The associated region at 3q13.2 contains CCDC80,
and CCDC80 is involved in induction of CEBPα and
peroxisome proliferator-activated receptor (PPAR)
γ.60 CEBPis expressed in basal keratinocytes and
upregulated while keratinocytes exit the basal layer
and undergo terminal differentiation.61 The associ-
ated region at 7p22 contains CARD11, which encodes
CARMA1, an essential scaffold protein for lympho-
cyte activation via T cell receptor and B cell receptor
signaling.62 CARMA1 has a critical role in the regula-
tion of JunB and GATA3 transcription factors and
subsequent production of Th2 cell-specific cytoki-
nes.63 Interestingly, mice homozygous for the Carma-
1 mutation gradually develop atopic dermatitis with
hyper-IgE.64 The region of association at 10q21.2 con-
tains EGR2, a T cell anergy-associated transcription
factor that activates the expression of genes involved
in the negative regulation of T cell proliferation and
inflammation.65 The associated region at 20q13 in-
cludes CYP24A1, which encodes a mitochondrial cy-
tochrome p450 superfamily enzyme. The protein acts
as a degradation enzyme of 1,5-dihydroxyvitamin D3,
the active form of vitamin D3.66 Vitamin D is a modu-
lator of innate and adaptive immune system func-
tions, and plays a crucial role in production of antimi-
crobial peptides in skin.66 A recent study has shown
an association between vitamin D deficiency and the
severity of atopic dermatitis.67 Topical glucocorticoids
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Fig.　1　The allergic march is the natural history of allergies. Symptoms often ap-
pear in a particular sequence during childhood.
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and the immunosuppressive agent tacrolimus are cur-
rently the mainstays of atopic dermatitis treatment.
However, there are some patients whose symptoms
are not well controlled. Since vitamin D ointment is
commonly prescribed to relieve some of the dry skin
symptoms associated with psoriasis, further clinical
studies on whether vitamin D ointment is effective for
atopic dermatitis seem to be needed.
GWASs OF ALLERGIC RHINITIS AND
EOSINOPHILIC ESOPHAGITIS
A large-scale genome-wide meta-analysis identified
several loci associated with allergic rhinitis and grass
sensitization.68 The chromosome 11q13.5 region,
which is near C11orf30 and LRRC32, is associated
with both phenotypes with genome-wide significance
(P < 5 × 10－8).68 LRRC32 is a key receptor controlling
FOXP3 in human regulatory T cells, which are critical
for maintaining tolerance.69 The 11q13.5 region has
already been reported as a susceptibility locus for
atopic dermatitis and asthma.38,46 In the GWAS, the
HLA region was also associated with grass sensitiza-
tion at the genome-wide level of significance.68
Eosinophilic esophagitis (EoE) is inflammation of
the esophagus with abnormal infiltration of eosino-
phils in an allergic reaction. A recent GWAS reported
that a candidate locus at chromosome 5q22 contained
TSLP and was associated with EoE.70 Interestingly,
recent GWASs have identified an association of the
TSLP region with bronchial asthma.27,29 In one study
TSLP was found to be overexpressed in esophageal
biopsies from individuals with eosinophilic esophagi-
tis compared with unaffected individuals, and TSLP
expression levels were significantly correlated with
the disease-related rs3806932 SNP in EoE cases.70
GENETIC COMPONENTS OF ALLERGIC
MARCH
Recent GWASs have revealed shared immunological
mechanisms in several immune-related diseases.71 A
number of GWASs of allergic diseases have revealed
that different allergic diseases share overlapping sus-
ceptibility loci. Among regions identified by GWASs
with genome-wide significance, the IL-1 receptor clus-
ter region on 2q12, the HLA and IL13 regions were
found to be associated with both atopic dermatitis
and bronchial asthma.24,29,48,53 The C11orf30
LRRC32 region on chromosome 11q13.5 is associ-
ated with atopic dermatitis, bronchial asthma and al-
lergic rhinitis.38,46,68 The allergic march is the natural
history of allergies and their symptoms often appear-
ing in a particular sequence during childhood, and
atopic dermatitis often represents the beginning of
this allergic march (Fig. 1).72 Recent studies have
shown that about half of the patients with atopic der-
matitis will develop bronchial asthma, particularly
with severe atopic dermatitis, and two-thirds will de-
velop allergic rhinitis.72 Since patients with the aller-
gic march often show a severe phenotype, further
studies of these overlapping loci (Fig. 1) might help
to clarify the mechanisms underlying this phenome-
non.
FUTURE PERSPECTIVES
Although GWASs have identified disease susceptibil-
ity loci of human diseases and provided valuable in-
sights into their genetic components, they have ex-
plained little of heritability, and the associated vari-
ants have small effect sizes.73 Potential sources of
missing heritability include unmapped common and
rare variants, copy number variations, epigenetic ef-
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fects, gene-gene interactions and gene-environment
interactions.74 Recently, the Immunochip has been
developed to conduct deep replication of major auto-
immune and inflammatory diseases, and fine-
mapping of established loci identified by GWASs.74,75
The Immunochip is a custom Illumina Infinium high-
density array containing 196,524 polymorphisms se-
lected using data from the 1000 Genomes Project
and other available disease-specific resequencing
data.74-76 The Immunochip approach might improve
our understanding of allergic diseases; however, the
Immunochip does not cover the whole genome and is
designed for use in white European populations.
Thus it would seem to be less informative for Asian
populations.
The 1000 Genomes Project is the first project to se-
quence the genomes of a large number of people to
provide a comprehensive resource on human genetic
variation.76 The project aims to find essentially all
variants with frequencies >1% across the genome and
>0.1% in protein-coding regions.76 It is considered
that imputations based on the 1000 Genomes Project
can increase the opportunity to find novel association
signals in GWAS meta-analyses through the dense
marker map and large number of haplotypes.14 Since
various GWAS consortiums for allergic diseases have
recently been formed, meta-analyses of GWASs using
the 1000 Genome Project data will identify novel
disease-associated regions.
Candidate genes at the susceptible loci identified
by GWASs of allergic diseases suggest roles for epi-
dermal barrier functions, innate and adaptive immu-
nity, IL-1 signaling, the inflammatory response, regu-
latory T cells and the vitamin D pathway in the patho-
genesis of allergic disorders. In immunology, consor-
tium biology has been conducted to establish com-
plete charts of all the molecular components that play
roles in cells of the immune system.77 To construct
animal models that mimic human physiology, the
findings of GWASs will be helpful to highlight the
genes involved in human allergic diseases.
Epigenetic regulation plays an important role in
mediating environmental influences on gene expres-
sion.78 Promoter methylation, histone tail modifica-
tions and altered expression of non-coding RNAs in-
fluence gene regulation and are candidate targets for
genetic associations.79 A recent study reported
sequence-dependent allele-specific DNA methylation
and that cis-regulatory variants influence gene expres-
sion and affect chromatin states.80 Sequence variants
can influence communication between different parts
of the genome, and SNPs might alter chromatin net-
works in a genotype-specific manner.81 It is known
that the human genome encodes -100 evolutionarily
conserved families of micro RNAs (miRNAs), and
SNPs can also directly affect miRNA binding sites.7
Further epigenetic analysis using GWAS SNPs and
their LD regions are required.
CONCLUSION
In the past century, most biological research has
been hypothesis-driven investigation performed in in-
dividual laboratories.77 Recent GWASs and meta-
analyses of the that comprehensively assess genes re-
lated to multifactorial diseases in a non-biased man-
ner across the whole genome have enhanced our un-
derstanding of human allergic diseases. Further
cross-disciplinary studies combining genetics, immu-
nology, epidemiology, and clinical allergology are
necessary for translation of research into clinical
practice. It is anticipated that the cross-disciplinary
studies will help to protect humans from developing
allergic diseases and provide molecular targets for
therapeutic intervention.
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